Trade INAB stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
IN8bio, Inc. (INAB) is trading at US$1.14, up 7.55% today as of Sep 22, 16:00 EDT. The company has a market capitalisation of US$12.62M. Over the past 52 weeks, INAB has traded between US$0.88 and US$2.73. On Syfe you can trade INAB with $0 commission and add it to your watchlist.
| Previous close | US$1.06 |
|---|---|
| Market cap | US$12.62M |
| 52-week range | US$0.88 – US$2.73 |
| Volume | 38.44K |
| Exchange | US |
Add to Watchlist
Set Price Alert
IN8bio, Inc.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Year: 2021
IN8bio, Inc. (INAB) stock is trading at US$1.14, +7.55% from the previous close of US$1.06.
The market cap for IN8bio, Inc. (INAB) stock is approximately US$12.62M.
The 52-week high for IN8bio, Inc. (INAB) stock is US$2.73.
The 52-week low for IN8bio, Inc. (INAB) stock is US$0.88.
IN8bio, Inc. (INAB) does not currently pay a dividend.
Stay on top of INAB
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
